Mbiomics, a biotechnology company focused on microbiome-derived therapies for chronic and severe diseases, has raised a total of €30 million in Series A financing following a third closing of €12 million.
Existing backers including MIG Fonds and Bayern Kapital participated in the round. The funding is intended to move the company from platform development into clinical studies while expanding manufacturing capacity.
What The Company Does
Founded in 2020 by Johannes Wöhrstein, Markus Rinecker, and Laura Figulla, Mbiomics is developing therapeutic products based on the human gut microbiome. The company’s approach centres on analysing microbial ecosystems and designing targeted bacterial communities that can address specific disease states and patient needs.
Its lead product category is Live Biotherapeutic Products (LBPs), oral medicines containing live bacterial strains intended to restore functional balance in the gut microbiome. These therapies are produced in a pharmaceutical-grade format designed for consistency and scale.
The company argues that while faecal microbiota transplants have demonstrated clinical promise, they often face challenges around standardisation, reproducibility, and industrial scalability. Mbiomics is positioning its platform as a more controlled alternative for regulated therapeutic use.
Advertisement
Market Context / Industry Background
Interest in microbiome therapeutics has grown steadily as research continues to link gut bacteria to immune regulation, metabolism, inflammation, and neurological function. Investors and pharmaceutical groups have increasingly viewed the field as a long-term growth segment, although commercial progress has been slower than initially expected due to scientific and manufacturing complexity.
One of the most active areas of development is oncology, where emerging evidence suggests the gut microbiome may influence patient responses to immune checkpoint inhibitors. If clinically validated, microbiome-based co-therapies could become an important complement to existing cancer treatments.
Europe has also remained an active hub for microbiome innovation, supported by strong academic research networks and expanding biotech investment across Germany, France, and the Nordics.
Meanwhile, advances in sequencing technology and computational biology are improving researchers’ ability to identify specific bacterial strains and understand their therapeutic potential. This is helping move the field beyond broad probiotic concepts toward more targeted, evidence-driven interventions. Pharmaceutical companies are also showing greater interest in partnerships with specialist startups to access proprietary platforms and clinical pipelines. As regulatory pathways become clearer, the sector may see faster progression from early-stage trials to larger commercial opportunities, particularly in immunology, gastrointestinal disease, and precision medicine. Interest is also growing in personalised therapies tailored to individual microbiome profiles and treatment responses worldwide globally.
Founder / Investor Commentary
Chief executive and co-founder Dr Johannes B. Woehrstein said the medical promise of the microbiome is already well recognised, but converting that science into scalable products has remained difficult. He said Mbiomics is addressing that challenge by building an integrated technology stack covering design, analysis, screening, and manufacturing of complex microbial consortia.
He added that the company is now focused on advancing its lead candidate MBX-116 toward clinical evaluation.
Growth Plans / Use Of Funds
The newly raised capital will be used to strengthen IND-enabling pharmacological data packages and accelerate GMP development and manufacturing ahead of human studies.
Mbiomics plans to begin a Phase 1B clinical study in 2027 for MBX-116, initially targeting second-line melanoma as a co-therapy designed to improve treatment response.
Beyond oncology, the company is also developing a wider pipeline with potential applications in autoimmune and neurodegenerative diseases, where microbiome modulation is increasingly being studied as a therapeutic pathway.
About Mbiomics
Mbiomics is a biotechnology company developing microbiome-based therapeutics for serious diseases. Founded in 2020 and headquartered in Bavaria, Germany, the company focuses on using data-driven microbial design and scalable manufacturing to create precision treatments based on the human gut microbiome.
